Fig. 4

Portal and periportal inflammation has disappeared at 12 months after BMMNCs administration. a Moderate portal and periportal inflammation with dense infiltration of lymphocytes and plasma cells. b inflammatory cells can no longer be observed in the portal and periportal areas